Endocrinology

The diabetes management and adult health specialist reacts to the SGLT2 inhibitor's newest indication.

The SGLT2 inhibitor from Janssen has shown significant benefit for reducing progression to end-stage kidney disease, as well as risk for major adverse cardiovascular events.

Vanita Aroda, MD, of Brigham and Women's Hospital, discusses the impact of PIONEER trials and the implications the approval for oral semaglutide has on diabetes care.

A recent study into insulin use in adults 75 and older found insulin use was increased in those with worse health, indicating a lack of adherence to current guideline recommendations.

In new research published in the New England Journal of Medicine, investigators led by William Tamborlane, M.D., a Yale University pediatric endocrinologist, reported the efficacy of the GLP1 agonist liraglutide for children with type 2 diabetes. In this Q&A, Dr. Tamborlane discusses the importance of expanding treatment options.

The therapy becomes the first oral GLP-1 agonist approved for the treatment of A1C reduction.

A recent study examining use of popular glucose-lowering medications found that metformin use was associated with fewer cardiovascular events in diabetic patients with reduced kidney function.

A new meta-analysis presented at EASD 2019 found that women who gave birth following use of assisted reproductive techniques had a 53% increased risk of gestational diabetes compared to women who conceived naturally.

Men with diabetes may have a higher risk of experiencing chronic lower back pain, say researchers writing in BMJ Open this month. 

How new dapagliflozin findings from ESC 2019 and HFSA 2019 shape our understanding of the SGLT-2 inhibitor's benefit.

The headline drug class has been quickly added to cardiologists' toolsets, amid more and more phase 3 data.

How do a pair of burgeoning agents influence endocrinology and renal outcomes in cardiovascular care?

The scope and scale of kidney disease is on the rise—much like its most commonly associated conditions.

FDA announced the approval of the glucagon (Gvoke) injection for the treatment of severe hypoglycemic events in diabetic patients ages 2 and up on September 10.

Normal thyroid stimulating hormone levels don't necessarily stave off all-cause mortality for hypothyroid patients, but adverse outcomes may intensify if levels fall below or above the norm.

Estrogen-based hormone therapy may not be associated with reduced loss of lean body mass compared with no hormone therapy in postmenopausal women, find researchers writing in JAMA Network Open last month.

By allocating 1% of their day to exercise, patients can turn an unhealthy lifestyle into a healthy lifestyle.

An analysis of CREDENCE, EMPA-REG, the CANVAS Program, and DECLARE-TIMI 58 found SGLT2 inhibitor use reduced dialysis, transplantation, or death due to kidney disease by 33%.

A 60-year-old woman undergoing hemodialysis for chronic kidney disease visited her physician with concerns about a painful smooth plaque on her leg that developed over the last few weeks. What's your diagnosis?

New findings from the THEMIS trial show patients with stable coronary artery disease and type 2 diabetes mellitus face major bleeding risks from the combination regimen.

Results of the DAPA-HF study — presented at the ESC Congress 2019, reveal use of dapagliflozin reduce hospitalizations from heart failure and deaths from cardiovascular causes in patients with heart failure with reduced ejection fraction.

The European Society of Cardiology and European Association for the Study of Diabetes released new diabetes and cardiovascular guidelines during ESC Congress 2019.

A lot has changed over the course of 10 years in solo practice, writes Melissa Young, M.D., in this month's Endocrine Feedback column. Dr. Young describes a decade of changes for the solo endocrinology practitioner. 

The SGLT-2 inhibitor is seeking an additional indication for primary renal outcome prevention in patients with or without type 2 diabetes.